Nobazit, capsules 250 mg 20 pcs

Pharmacotherapeutic group: Antiviral drug.

ATC code: J05 AH

Pharmacological properties

Pharmacodynamics

Nobazit® is an antiviral agent, a derivative of isonicotinic acid. It effectively suppresses influenza viruses and other agents of acute respiratory viral infections due to the direct (inhibitory) influence on the process of virus penetration through the cell membrane.
It possesses interferonogenic properties, increases the concentration of endogenous interferon (interferon alpha and interferon gamma) in blood plasma by 3-4 times. Increases body resistance to viral infections.
Reduces acute clinical manifestations of viral intoxication, helps to reduce the duration of the disease.

Pharmacokinetics

After oral administration enisamide iodide quickly enters the blood, its maximum concentration in the blood is observed 2-2.5 hours after consumption. Enisamy iodide and its metabolites circulate in the bloodstream for a long time (half-life is 13.5-14 hours), are metabolized in the liver and are quickly eliminated from the tissues (half-life is 2-3 hours). It is 90-95% excreted in the urine as metabolites.

Indications

Active ingredient

Composition

How to take, the dosage

Start treatment at the first signs of the disease. If after 3 days of treatment there is no improvement or the symptoms worsen, or new symptoms appear, you should consult a doctor. Use only with the directions, route of administration, and amount prescribed.

Nobasite® is taken orally after a meal, without chewing, 0.5 g three times daily.

The maximum single dose is 1 g, the daily dose is 2 g.

The recommended course of treatment is from 5 to 7 days.

Interaction

Special Instructions

Influence on ability to drive vehicles and mechanisms

The administration of Nobazit® has no effect on the ability to drive vehicles and various mechanical equipment.

Contraindications

Side effects

Allergic reactions: hypersensitivity reactions, including skin rashes, urticaria, angioedema, itching.

Digestive system disorders: dryness and bitter taste in the mouth, swelling of the oral mucosa, hyper salivation, yellow discoloration of the tongue, nausea, vomiting, heartburn, abdominal pain, heaviness in the right subcostal area, diarrhea, abdominal bloating.

Respiratory system: shortness of breath, throat irritation.

In the post-registration period, the following adverse reactions have been reported in single cases: headache, dizziness, weakness, blood pressure fluctuations.

If you have any of the side effects mentioned in the instructions, or if they get worse, or if you notice any other side effects not mentioned in the instructions, tell your doctor.

Overdose

Pregnancy use